Results 61 to 70 of about 5,561 (172)

Characterization and comparison of deferasirox fast disintegrating tablets prepared by direct compression and lyophilization methods

, 2020
Objectives: The aim of this study was to develop direct compressed and lyophilized fast disintegrating/dissolving tablets (FDTs) that enhanced disintegration and dissolution of deferasirox, a drug with poor solubility and bioavailability.
ÖNER, LEVENT, AKDAĞ ÇAYLI, YAĞMUR, Akdag, Yagmur, ÇETİN, Meltem, GÜLSÜN İNAL, TUĞBA, İZAT, NİHAN, ŞAHİN, SELMA, Gulsun, Tugba   +7 more
core   +1 more source

Deferasirox-induced cytogenetic responses

, 2015
PubMedID: 25733130Deferasirox (commercially formulated as Exjade®) is one of the effective iron chelators used in treatment of iron overload diseases.
Ila H.B., Arslan M.
core   +1 more source

Bilateral Nuclear Cataract with Deferasirox in a Patient of Beta-thalassemia: A Case Report and Literature Review

Delhi Journal of Ophthalmology
We report the case of a 15-year-old child with beta-thalassemia developing bilateral cataracts while receiving deferasirox, a newer iron chelator. She had been taking deferasirox for the past 10 years while receiving monthly blood transfusions.
Tushit Dhar, Vaishali Tomar, Subhash Dadeya   +2 more
doaj   +1 more source

Dose-dependent change in LIC with deferasirox treatment ▪ Deferasirox; □ DFO

, 2011
Copyright information:Taken from "Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion"Therapeutics and Clinical Risk Management 2007;3(2):291-299.Published online Jan 2007PMCID:PMC1936310.© 2007 Dove
Maria Domenica Cappellini (77687)
core   +1 more source

Deferasirox as adjunctive therapy for mucormycosis.

, 2012
Item does not contain fulltextMucormycosis can be devastating and, as yet, there are no ideal therapies available. Observations that iron chelation may be a useful adjunct to antifungal treatment encouraged Spellberg et al.
Donnelly, J.P., Lahav, M.
core   +1 more source

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.

PLoS ONE, 2018
Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron
Francesca Punzo, Chiara Tortora, Maura Argenziano, Maddalena Casale, Silverio Perrotta, Francesca Rossi   +5 more
doaj   +1 more source

Gastric ulcer in a child treated with deferasirox

, 2010
We present a patient with thalassemia major who developed a gastric ulcer, probably related to the use of deferasirox. Although gastric ulcer is mentioned as infrequent adverse event in the scientific product information of deferasirox, in our current ...
De Moerloose, Barbara, Mondelaers, Veerle, HUNNINCK, KATHLEEN, Robays, Hugo, Bauters, Tieneke   +4 more
core   +1 more source

Nefrotoxicidad por deferasirox [PDF]

, 2016
Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina. Fecha de lectura: 12-12-2016Introducción: El deferasirox es un quelante de hierro oral utilizado como terapia de primera línea para la ...
Gallegos Villalobos, Angel
core  

Ferritin level changes and erythroid improvement in a group of adult politransfused patients treated with Deferasirox

, 2018
Background and aims. Chelating agents therapy is recommended for polytransfused patients that have evidence of iron overload (an elevated serum ferritin or received over 20 units of red blood cell transfusions).
Iulia Andrea Zsoldos, Mihaela Iancu, Laura Urian, Anca Bojan, Tunde Torok, Andrada Viorica Parvu   +5 more
core   +1 more source

Új deferasiroxszármazékok előállítása és vizsgálata

, 2020
A diplomamunka célja deferasiroxból kiindulva ambidentát ligandumok, illetve ezek Co(III) és Ru(II) illetve kétfémes Co(III)/Ru(II) komplexeinek előállítása volt.
Vas, Péter Mihály
core